For WA's retiring Chief Health Officer Andy Robertson, the 2020 spread of the "novel coronavirus" was not the first time he ...
GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial ...
The recent advances in basic and applied research of medical countermeasures against inhalation anthrax have been remarkable. Since 2001, the US government has made more than US$40 billion available ...
YONGIN, South Korea, April 9, 2025 /PRNewswire/ -- GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly ...
Anthrax, an infectious disease caused by the bacterium Bacillus anthracis, is often treatable in its early stages. But once the disease has progressed beyond the "point of no return" after just a few ...
Shihui Liu, M.D., Ph.D., associate professor of medicine at the University of Pittsburgh School of Medicine and member of the Aging Institute, a joint venture of Pitt and UPMC Anthrax, an infectious ...
Abstract: A detection scheme for Anthrax toxins based on the interaction of an ion channel formed by protective antigen 63 (PA63)7, a heptameric ion channel forming toxin, with lethal factor is ...
Bacillus anthracis lethal toxin (LT) is a determinant of lethal anthrax. Its function in myeloid cells is required for bacterial dissemination, and LT itself can directly trigger dysfunction of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback